Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

44,183 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial.
Röth A, Berentsen S, Barcellini W, D'Sa S, Jilma B, Michel M, Weitz IC, Yamaguchi M, Nishimura JI, Vos JMI, Storek M, Wong N, Patel P, Jiang X, Vagge DS, Wardęcki M, Shafer F, Lee M, Broome CM. Röth A, et al. Among authors: lee m. Blood. 2022 Sep 1;140(9):980-991. doi: 10.1182/blood.2021014955. Blood. 2022. PMID: 35687757 Free PMC article. Clinical Trial.
Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up results.
Roth A, Barcellini W, D'Sa S, Miyakawa Y, Broome CM, Michel M, Kuter DJ, Jilma B, Tvedt THA, Weitz IC, Patel P, Jiang X, Reuter C, Su J, Shafer F, Lee M, Berentsen S. Roth A, et al. Among authors: lee m. Haematologica. 2022 Jul 1;107(7):1698-1702. doi: 10.3324/haematol.2021.279812. Haematologica. 2022. PMID: 35172561 Free PMC article. No abstract available.
Sutimlimab provides clinically meaningful improvements in patient-reported outcomes in patients with cold agglutinin disease: Results from the randomised, placebo-controlled, Phase 3 CADENZA study.
Röth A, Broome CM, Barcellini W, Jilma B, Hill QA, Cella D, Tvedt THA, Yamaguchi M, Lee M, Shafer F, Wardęcki M, Jiang X, Patel P, Joly F, Weitz IC. Röth A, et al. Among authors: lee m. Eur J Haematol. 2023 Mar;110(3):280-288. doi: 10.1111/ejh.13903. Epub 2022 Dec 9. Eur J Haematol. 2023. PMID: 36403132 Clinical Trial.
Cost effectiveness of hepatitis C direct acting agents.
Shetty A, Lee M, Valenzuela J, Saab S. Shetty A, et al. Among authors: lee m. Expert Rev Pharmacoecon Outcomes Res. 2024 Jun;24(5):589-597. doi: 10.1080/14737167.2024.2348053. Epub 2024 May 3. Expert Rev Pharmacoecon Outcomes Res. 2024. PMID: 38665122 Review.
Extracranial Vertebral Artery Injuries.
Lee MJ, Weaver DJ, El Dafrawy MH. Lee MJ, et al. J Am Acad Orthop Surg. 2024 May 28. doi: 10.5435/JAAOS-D-24-00244. Online ahead of print. J Am Acad Orthop Surg. 2024. PMID: 38810231
44,183 results
You have reached the last available page of results. Please see the User Guide for more information.